TME PHARM.CONF.IPO EO 1- (0N6A) — Tangible Net Worth Ratio
TME PHARM.CONF.IPO EO 1- (0N6A) has a Tangible Net Worth Ratio of 99.8% as of December 2024. This metric is calculated by deducting intangible assets (€4.00K) from net assets (€1.61 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore 0N6A shareholders equity momentum to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
TME PHARM.CONF.IPO EO 1- Tangible Net Worth Ratio (2021–2024)
This chart shows how TME PHARM.CONF.IPO EO 1-'s Tangible Net Worth Ratio has changed across 2 annual periods from 2021 to 2024. As of December 2024, the ratio stands at 99.8%, reflecting net assets of €1.61 Million with intangible assets of €4.00K EUR. For live market cap and overall valuation, see TME PHARM.CONF.IPO EO 1- (0N6A) market capitalisation.
Annual Tangible Net Worth Ratio for TME PHARM.CONF.IPO EO 1- (2021–2024)
The table below presents the year-by-year Tangible Net Worth Ratio for TME PHARM.CONF.IPO EO 1- from 2021 to 2024, covering 2 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. See 0N6A FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
| Year | Tangible NW Ratio | Net Assets (EUR) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 99.8% | €1.61 Million | €4.00K | €3.41 Million | ▼ -0.2 pp |
| 2021 | 99.9% | €4.50 Million | €4.00K | €9.77 Million | — |